美联邦政策调整前后阿片类药物治疗项目纳洛酮剂量调整对美沙酮涉及的过量死亡的影响
Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs.
机构信息
National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
出版信息
JAMA Psychiatry. 2022 Sep 1;79(9):932-934. doi: 10.1001/jamapsychiatry.2022.1776.
Abstract
This observational study assesses whether methadone-involved overdose deaths decreased when opioid treatment programs take-home policies changed during the COVID-19 pandemic.
摘要
本观察性研究评估了在 COVID-19 大流行期间，阿片类药物治疗计划改变了美沙酮相关药物过量死亡是否减少。
相似文献
1
Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs.
JAMA Psychiatry. 2022 Sep 1;79(9):932-934. doi: 10.1001/jamapsychiatry.2022.1776.
2
Medicines for Patients After an Opioid Overdose.
Ann Intern Med. 2018 Aug 7;169(3). doi: 10.7326/P18-0009. Epub 2018 Jun 19.
3
History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018-June 30, 2020.
Am J Public Health. 2021 Sep;111(9):1600-1603. doi: 10.2105/AJPH.2021.306395. Epub 2021 Aug 19.
4
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Drug Alcohol Depend. 2023 Jan 1;242:109703. doi: 10.1016/j.drugalcdep.2022.109703. Epub 2022 Nov 19.
5
Prevention of Opioid Overdose.
N Engl J Med. 2019 Jun 6;380(23):2246-2255. doi: 10.1056/NEJMra1807054.
6
Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis.
Drug Alcohol Depend. 2022 Sep 1;238:109565. doi: 10.1016/j.drugalcdep.2022.109565. Epub 2022 Jul 7.
7
Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
J Subst Abuse Treat. 2021 Dec;131:108449. doi: 10.1016/j.jsat.2021.108449. Epub 2021 Apr 29.
8
Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Addiction. 2022 Jul;117(7):1972-1981. doi: 10.1111/add.15862. Epub 2022 Mar 21.
9
Comparing methadone policy and practice in France and the US: Implications for US policy reform.
Int J Drug Policy. 2024 Jul;129:104487. doi: 10.1016/j.drugpo.2024.104487. Epub 2024 Jun 14.
10
Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
Int J Drug Policy. 2024 Feb;124:104302. doi: 10.1016/j.drugpo.2023.104302. Epub 2024 Jan 5.
引用本文的文献
1
Interrogating perceived relevance and feasibility of HIV pre-exposure prophylaxis: A novel model of PrEP acceptability among cisgender women who inject drugs.
SSM Qual Res Health. 2023 Dec;4. doi: 10.1016/j.ssmqr.2023.100337. Epub 2023 Sep 14.
2
Innovations at the intersection of homelessness and substance use during the COVID-19 pandemic: a scoping review.
Harm Reduct J. 2025 Jul 29;22(1):132. doi: 10.1186/s12954-025-01235-7.
3
Methadone-involved overdose deaths in urban and rural communities before and after the public health emergency flexibilities for methadone take-home doses.
Drug Alcohol Depend Rep. 2025 Apr 24;15:100339. doi: 10.1016/j.dadr.2025.100339. eCollection 2025 Jun.
4
Impact of guidance issued during COVID-19 to expand take-home doses of opioid agonist treatment (OAT) in Ireland: protocol for a population-based analysis of prescribing practices and patient outcomes 2018 to 2023.
HRB Open Res. 2025 Apr 7;8:32. doi: 10.12688/hrbopenres.14044.2. eCollection 2025.
5
Comparative effectiveness of methadone take-home dose initiation in British Columbia, Canada: protocol for a population-based retrospective cohort study using target trial guidelines.
BMJ Open. 2025 Mar 5;15(3):e095198. doi: 10.1136/bmjopen-2024-095198.
6
Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.
Addict Sci Clin Pract. 2025 Feb 4;20(1):7. doi: 10.1186/s13722-025-00537-2.
7
State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States.
Subst Use Misuse. 2025;60(4):531-541. doi: 10.1080/10826084.2024.2440365. Epub 2024 Dec 31.
8
Clinician and Practice Characteristics Associated With Support of Office-based Methadone: Findings From a National Survey.
J Addict Med. 2025;19(2):150-156. doi: 10.1097/ADM.0000000000001388. Epub 2024 Oct 30.
9
Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.
JAMA. 2024 Dec 3;332(21):1822-1831. doi: 10.1001/jama.2024.16954.
10
Methadone Take-Home Policies and Associated Mortality: Permitting versus Non-Permitting States.
Subst Use. 2024 Aug 16;18:29768357241272379. doi: 10.1177/29768357241272379. eCollection 2024 Jan-Dec.
Zotero 插件